Cullgen’s oncology portfolio features TRK, GSPT1 and CDK2 degraders.
ApexOnco Front Page
Recent articles
But now it must show that varseta-M can move into a registrational trial.
Bristol will test the bispecific in two new lung indications.
The latest onvansertib data, and an abrupt CEO departure, spook investors.
New pivotal trials of HRS-8080 are planned in first-line and adjuvant breast cancer.
After Genmab’s exit two more ADCs enter human trials.
A new phase 3, Manifest-3, will start in April to support US filing.
The company takes a PD-L1 x VEGF asset into phase 3.
